tiprankstipranks
Protagenic Therapeutics (PTIX)
NASDAQ:PTIX

Protagenic Therapeutics (PTIX) Income Statement

24 Followers

Protagenic Therapeutics Income Statement

Last quarter (Q ), Protagenic Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Protagenic Therapeutics's net income was $-1.40M. See Protagenic Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 322.04K--$ 0.00$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
$ 322.04K-----
Operating Expense
$ 1.18M$ 3.56M$ 4.14M$ 2.55M$ 2.09M$ 2.31M
Operating Income
$ -2.16M$ -3.60M$ -4.14M$ -2.55M$ -2.09M$ -2.31M
Net Non Operating Interest Income Expense
$ -206.29K$ 48.33K$ -380.04K$ -245.68K$ -13.07K$ 2.79K
Other Income Expense
$ 247.42K$ 421.74K$ 77.03K$ 248.55K$ 348.29K$ -246.19K
Pretax Income
$ -3.93M$ -3.56M$ -4.60M$ -2.55M$ -1.75M$ -2.56M
Tax Provision
---$ 0.00$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -2.46M$ -3.98M$ -4.60M$ -2.55M$ -1.75M$ -2.56M
Basic EPS
$ -1.42$ -0.82-$ -0.25$ -0.17$ -0.25
Diluted EPS
$ -0.77$ -0.82$ -1.24$ -0.25$ -0.17$ -0.25
Basic Average Shares
$ 17.30M$ 4.32M$ 3.69M$ 10.34M$ 10.26M$ 10.26M
Diluted Average Shares
$ 12.98M$ 4.32M$ 3.69M$ 10.34M$ 10.26M$ 10.26M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 1.18M$ 3.56M$ 4.14M$ 2.55M$ 2.09M$ 2.31M
Net Income From Continuing And Discontinued Operation
$ -3.99M$ -3.56M$ -4.60M$ -2.55M$ -1.75M$ -2.56M
Normalized Income
$ -2.06M--$ -2.80M$ -2.10M$ -2.31M
Interest Expense
---$ 246.18K$ 15.89K$ 0.00
EBIT
$ -3.57M$ -3.42M$ -4.22M$ -2.30M$ -1.74M$ -2.56M
EBITDA
$ -3.46M$ -3.31M$ -3.79M$ -2.30M$ -1.73M$ -2.56M
Currency in USD

Protagenic Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis